Country: Canada
Language: English
Source: Health Canada
EVEROLIMUS
PHARMASCIENCE INC
L04AH02
EVEROLIMUS
5MG
TABLET
EVEROLIMUS 5MG
ORAL
15G/50G
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0152682001; AHFS:
APPROVED
2020-09-04
_pms-EVEROLIMUS (everolimus)_ _Page 1 of 91_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr PMS-EVEROLIMUS Everolimus Tablets Tablets, 2.5 mg, 5 mg and 10 mg, Oral Protein Kinase inhibitors ATC Code: L01XE10 PHARMASCIENCE INC. 6111 Royalmount Ave., Suite 100 Montréal, Québec H4P 2T4 www.pharmascience.com Submission Control Number: 256066 Date of Initial Authorization 4 SEP 2020 Date of Revision: 27 JAN 2022 _pms-EVEROLIMUS (everolimus)_ _Page 2 of 91_ RECENT MAJOR LABEL CHANGES 1.1 Pediatrics 01/2022 4.1 Dosing Considerations 01/2022 4.4 Administration, Switching Dosage Forms 01/2022 7 WARNINGS AND PRECAUTIONS, Radiation Sensitization and Radiation Recall 01/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ..................................................................................... 2 TABLE OF CONTENTS .......................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION............................................................... 4 1 INDICATIONS ................................................................................................................... 4 1.1 Pediatrics ................................................................................................................. 5 1.2 Geriatrics ................................................................................................................. 5 2 CONTRAINDICATIONS..................................................................................................... 6 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................. 6 4 DOSAGE AND ADMINISTRATION .................................................................................... 7 4.1 Dosing Considerations ............................................................................................. 7 4.2 Recommended Dose and Dosage Adjustment.. Read the complete document